31
Jul
Mumbai (Maharashtra) [India], July 31: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and Animal Healthcare Products, has reported its Unaudited financials for Q1 FY26. Key Financial Highlights Particulars (₹ Cr) Q1 FY26 Q1 FY25 YoY Total Income 119.86 78.81 52.08% EBITDA 16.99 10.48 62.15% EBITDA Margin (%) 14.18 13.30 88 BPS Net Profit 6.77 4.13 63.82% Net Profit Margin (%) 5.64 5.24 40 BPS Diluted EPS (₹) 14.33 8.79 63.03% Commenting on the financial performance Mr. Fredun Medhora, Managing Director, said “We are pleased…